Health Condition 1: null- Patients having supratentorial tumours scheduled for craniotomy and excision of tumour
Conditions
Interventions
Intervention1: Magnesium: Group A will receive a bolus of magnesium sulphate(50%)50 mg/Kg followed by infusion 25 mg/Kg/hr intravenously till the surgery ends
Intervention2: Lignocaine: Group B will
Sponsors
AIIMS
Eligibility
Inclusion criteria
Inclusion criteria: Patients having supratentorial tumours undergoing elective craniotomy and excision of tumour.
Exclusion criteria
Exclusion criteria: patients having cardiovascular, respiratory, renal or hepatic disease, on treatment with calcium channel blockers, having brain tumour larger than 30 mm in any dimension, having mental diability, neurological or cognitive deficits (precluding their use of patient controlled analgesia device, having allergy to study medications, having history of myopathy or substance abuse. Patients who are mechanically ventilated in the postoperative period will be excluded from the final analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effect of magnesium and lignocaine on postoperative pain as assessed using visual analogue scale (VAS).Timepoint: To evaluate the effect of magnesium and lignocaine on postoperative pain as assessed using visual analogue scale (VAS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of study drugs if anyTimepoint: intraoperative period till 24 hours postoperatively;To asees S100 B levelsTimepoint: Baseline, at end of surgery and at 24 hrs postoperatively.;To determine total fentanyl consumptionTimepoint: intraoperative and 24 hours postoperatively | — |
Countries
India
Contacts
Public ContactDr Charu Mahajan
AIIMS
Outcome results
None listed